


13

## CLAIMS

1. Use of natural human  $\alpha$ -interferon for the preparation of a medicament in liquid form to be administered through peroral route at dosages comprised 5 between 100 UI and 500 UI/day, for therapy of viral hepatitis in humans and animals.
2. Use of natural human  $\alpha$ -interferon for the preparation of a medicament in liquid form to be administered through peroral route at dosages comprised 10 between 100 UI and 500 UI/day, for therapy of neoplasia and immunologic diseases in humans and animals.
3. Use of natural human  $\alpha$ -interferon according to claims 1 or 2 wherein said interferon is obtained from lymphoblastoid cell cultures.
- 15 4. Use of natural human  $\alpha$ -interferon according to claims 1 or 2 wherein said interferon is obtained from lymphocyte cells.
- 20 5. Use of natural human  $\alpha$ -interferon according to any of previous claims wherein said medicament is administered in mono dosage units of appr. 1 ml.
- 25 6. Pharmaceutical liquid composition for peroral administration comprising natural human  $\alpha$ -interferon either from lymphoblastoid cell cultures or from lymphocyte cells at a concentration between 100 UI/ml and 500 UI/ml.



PHARMACEUTICAL COMPOSITIONS COMPRISING NATURAL HUMAN  $\alpha$ -INTERFERON

Use of natural human  $\alpha$ -interferon for the preparation of a medicament in liquid form to be administered through peroral route at dosages comprised between 100 UI and 500 UI/day, for therapy of viral infections, in particular viral hepatitis, neoplasia and immune diseases in humans and animals.